AVENUE THERAPEUTICS, INC.

BAY HARBOR ISLANDS, FL · Founded 2015 · Biotech · Public

ATX-04, a therapeutic candidate for Pompe disease treatment

Claim this profile

Follows are private to you and power your alerts

Updated · avenuetx.com

Sector
Biotech
Headquarters
BAY HARBOR ISLANDS, FL
Founded
2015
Latest Form D
$243K, Feb 2023
Total capital
$443K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$443K
2 Form D · last Feb 2023
44 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2017201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $443K1st Form D$200K2nd Form D$243K
2017201920212023FEDERAL ↑EQUITY ↓Cumulative $443K1st Form D$200K2nd Form D$243K

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$243K
  • Private capital raisedForm D · SEC · 1st filing$200K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Akhtar A. Samad, M.D. Ph.D.DirectorNamed in SEC Form D filings
  • Alexandra A. MacLean, M.D.Executive OfficerNamed in SEC Form D filings
  • Curtis A. OltmansDirectorNamed in SEC Form D filings
  • David J. HorinExecutive OfficerNamed in SEC Form D filings
  • David A. JinExecutive OfficerNamed in SEC Form D filings
  • Faith A. CharlesDirectorNamed in SEC Form D filings
Show all 15 people
  • Jay A. Kranzler, M.D., Ph.D.DirectorNamed in SEC Form D filings
  • Jeffrey A. Paley, M.D.DirectorNamed in SEC Form D filings
  • Lindsay A. Rosenwald, M.D.DirectorNamed in SEC Form D filings
  • Lucy Lu, M.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Michael A. Ryan, M.S.Executive OfficerNamed in SEC Form D filings
  • Michael A. WeissDirectorNamed in SEC Form D filings
  • Neil A. HerskowitzDirectorNamed in SEC Form D filings
  • Scott A. Raines, M.D.Executive OfficerNamed in SEC Form D filings
  • Scott A. Reines, M.D., Ph.D.Executive OfficerNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Fairfield Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • GenrAb, Inc.Similar federal contract value in Biotech · null in contracts
  • INSYBIO INC.Similar federal contract value in Biotech · null in contracts
  • Medexus Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
  • Essential Remedium Corp.Similar federal contract value in Biotech · null in contracts
  • IMAGINE PHARMA LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .